⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 29, 2014Arthritis Research & TherapyOpen Access

Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

ClinicalTrials.gov NCT01225393, Registered 18 October 2010.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kennedy et al. (2014) studied this question.

synapsesocial.com/papers/69dbc31d3d9adb00e7684ed5 https://doi.org/10.1186/s13075-014-0467-3

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trialRCT · 2012 · 41 citations
2Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid SynoviumOriginal Research · 2009 · 546 citations
3The MOS 36-ltem Short-Form Health Survey (SF-36)Original Research · 1992 · 30,035 citations
4NETWORK COMMUNICATIONS: Lymphotoxins, LIGHT, and TNFOriginal Research · 2004 · 442 citations
5Revised Criteria for the Classification of Rheumatoid ArthritisOriginal Research · 1990 · 7,732 citations